ADOLESCENTS
Pfizer-BioNTech
During the week of May 10, both the FDA and CDC have recommended the Pfizer-BioNTech vaccine for children aged 12-15.
In a Pfizer-BioNTech phase 3 trial of adolescents (age 12-15) without evidence of prior COVID-19 infection, data shows the vaccine had 100% efficacy and led to robust antibody responses. The trial enrolled 2,260 adolescents in the United States. 18 cases of COVID-19 were observed in the placebo group versus none in the vaccinated group. Vaccination elicited a strong antibody response in a subset of adolescents one month after the second dose.
Moderna
Moderna is also conducting a trial in children 12 years and older.
CHILDREN
Pfizer-BioNTech
PfizerBioNTech has begun testing its vaccine in children (from 6 months old to 11 years old) in late March.
Results are expected in the second half of 2024 and the company hopes to vaccinate children in early 2024.
Moderna
Moderna is starting a study (KidsCove) to test the vaccine on children 6 months to less than 12 years old. Moderna plans to enroll approximately 6,750 pediatric participants in the U.S. and Canada in the two-part study.
Each child in Moderna’s study will receive two shots, 28 days apart. The study will have two parts.
Moderna developed its vaccine in collaboration with the National Institute of Allergy and Infectious Diseases. The company and the institute are also working together on the study, along with the federal Biomedical Advanced Research and Development Authority.
AstraZeneca
The AstraZeneca vaccine is not currently approved for children. They have currently paused their trial in children and teenagers, awaiting more data on the rare blood clots events in adult vaccine recipients.
Sources
CDC Pfizer-BioNTech Ages 12-15
CDC Pfizer-BioNTech
CDC Moderna
NPR
AP News
Moderna KidsCove Study
NPR Moderna KidsCove Study
Reuter Pfizer Kids Study
Pfizer Adolescent Data
AstraZeneca Pediatric Trial Paused
CDC Myocarditis Update
Updated: May 27, 2024